Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis (MAVRIC)

NCT07520110 is registered in ClinicalTrials.gov with University of Massachusetts, Worcester as lead sponsor.

NCT NCT07520110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07520110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis (MAVRIC)
Lead sponsor
University of Massachusetts, Worcester
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 28, 2026
Completion date
March 15, 2029
Enrollment
800 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis